All In Biotech

Drug Trial Radar · NCT00790907

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)

Last checked: Nov 20, 2026Latest source record: Mar 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 3,235 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,235

Actual

Start

Feb 2009

Primary completion

May 2010

Study completion May 2010

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST segment elevation myocardial infarction) who have been initially treated with fondaparinux.

Conditions

  • Acute Coronary Syndrome

Interventions

  • fondaparinux background and standard dose UFHDrug

    Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein \[GP\] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) \[maximum two additional bolus doses\]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.

  • Fondaparinux background and low dose heparinDrug

    Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.

  • Open label fondaparinuxDrug

    Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications During the Peri-PCI PeriodTime frame: Peri-PCI Period: occurred at randomization (from randomization to 48 hours after end of PCI procedure, typically 49 hours total)

Locations

203 sites in 18 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ocala, Florida

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina

  • GSK Investigational Site

    Adrogué, Buenos Aires, Argentina

  • GSK Investigational Site

    Bahía Blanca, Buenos Aires, Argentina

  • GSK Investigational Site

    La Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    Merlo, Buenos Aires, Argentina

  • GSK Investigational Site

    Quilmes, Buenos Aires, Argentina

  • GSK Investigational Site

    Quilmes, Buenos Aires, Argentina

  • GSK Investigational Site

    Rosario, Buenos Aires, Argentina

  • GSK Investigational Site

    Corrientes, Corrientes Province, Argentina

  • GSK Investigational Site

    Rosario, Santa Fe Province, Argentina

  • GSK Investigational Site

    Santa Fe, Santa Fe Province, Argentina

  • GSK Investigational Site

    Santa Fe, Santa Fe Province, Argentina

  • GSK Investigational Site

    Campina Grande do Sul, Paraná, Brazil

  • GSK Investigational Site

    Curitiba, Paraná, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Blumenau, Santa Catarina, Brazil

  • GSK Investigational Site

    Campinas, São Paulo, Brazil

  • GSK Investigational Site

    Marília, São Paulo, Brazil

  • GSK Investigational Site

    São José do Rio Preto, São Paulo, Brazil

  • GSK Investigational Site

    São José do Rio Preto, São Paulo, Brazil

  • GSK Investigational Site

    Plovdiv, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Hamilton, Ontario, Canada

  • GSK Investigational Site

    London, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Chicoutimi, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.